TIDMAGL
Angle PLC
04 September 2019
For immediate release 4 September 2019
ANGLE plc ("the Company")
MEDICAL UNIVERSITY OF VIENNA DEMONSTRATES USE OF PARSORTIX FOR
NEUROENDOCRINE ANALYSIS IN SMALL CELL LUNG CANCER
Neuroendocrine markers on CTCs associated with poor overall
survival
Potential for faster diagnosis, patient stratification and
on-treatment therapy monitoring in lung cancer
ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy
company, is pleased to announce that the Medical University of
Vienna (Vienna) has published new results of work undertaken in
small cell lung cancer (SCLC) utilising ANGLE's Parsortix(R)
system.
This has been published as a peer-reviewed publication in the
journal Cells and is available at
https://angleplc.com/library/publications/.
The work for the first time investigates neuroendocrine markers
on circulating tumor cells (CTCs) harvested by the Parsortix
system. These were found to correlate with patients' poor overall
survival. The investigation utilised RNA analysis on the CTCs,
which cannot be achieved by analysis of ctDNA (fragments of dead
cells).
SCLC is a highly aggressive neuroendocrine tumor of the lung and
most patients present with metastatic disease at initial diagnosis.
Utilising a Parsortix liquid biopsy based on a simple blood test
could have numerous advantages compared to current standard of care
including:
-- fast and accurate diagnosis of SCLC, which can be challenging
due to difficulties accessing the site and/or insufficient biopsied
tissue;
-- repeat liquid biopsies to guide treatment as the cancer
evolves, which is not feasible with tissue biopsies due to the
invasive injury to the patient, risks of medical complication and
the high costs of tissue biopsy in lung cancer;
-- determination by RNA analysis of the CTCs of suitable drugs
and whether new targeted lung cancer drugs are likely to be
effective for the patient.
Professor Robert Zeillinger, Head of the Molecular Oncology
Group at the Medical University of Vienna, commented:
"In this study we have demonstrated new approaches utilising
ANGLE's Parsortix system to assess neuroendocrine markers in lung
cancer. These markers correlate to the aggressiveness of the cancer
and have the potential to significantly improve the way that lung
cancer is diagnosed and treated."
ANGLE Founder and Chief Executive, Andrew Newland,
commented:
"Lung cancer is a major opportunity for ANGLE to pursue once we
have concluded our current FDA and verification studies in breast
cancer and ovarian cancer. We are encouraged by the work of Vienna,
and others, in this area. There is a clear benefit to lung cancer
patients in faster diagnosis, longitudinal monitoring and reducing
invasive procedures as well as a strong health economic argument to
reduce healthcare costs."
For further information ANGLE:
ANGLE plc +44 (0) 1483 343434
Andrew Newland, Chief Executive
Ian Griffiths, Finance Director
finnCap Ltd (NOMAD and Joint Broker)
Corporate Finance - Carl Holmes, Simon
Hicks, Max Bullen-Smith
ECM - Alice Lane, Sunila de Silva +44 (0)20 7220 0500
WG Partners (Joint Broker)
Nigel Barnes, Nigel Birks, Andrew Craig,
Chris Lee +44 (0) 203 705 9330
FTI Consulting
Simon Conway, Ciara Martin +44 (0) 203 727 1000
Matthew Ventimiglia (US) +1 (212) 850 5624
For Frequently Used Terms, please see the Company's website on
http://www.angleplc.com/the-parsortix-system/glossary/
Notes for editors
About Medical University of Vienna
Medical University of Vienna is one of the most traditional
medical education and research facilities in Europe. With almost
8,000 students, it is currently the largest medical training centre
in the German-speaking countries. With 5,500 employees, 27
departments and three clinical institutes, 12 medical theory
centres and numerous highly specialised laboratories, it is also
one of Europe's leading research establishments in the biomedical
sector.
About ANGLE plc www.angleplc.com
ANGLE is a world leading liquid biopsy company with
sample-to-answer solutions. ANGLE's proven patent protected
platforms include an epitope-independent circulating tumor cell
(CTC) harvesting technology and a downstream analysis system for
cost effective, highly multiplexed analysis of nucleic acids and
proteins.
ANGLE's cell separation technology is called the Parsortix(R)
system, and it enables a liquid biopsy (a simple blood test) to be
used to provide the cells of interest to the user in a format
suitable for multiple downstream subsequent analyses. CTCs enable
the complete picture of a cancer to be seen as they allow DNA, RNA
and protein analysis and the live cells harvested can be cultured.
The Parsortix technology is the subject of 24 granted patents in
Europe, the United States, China, Australia, Canada, India, Japan
and Mexico with three extensive families of patents are being
progressed worldwide. The system is based on a microfluidic device
that captures cells based on a combination of their size and
compressibility. The Parsortix system has a CE Mark in Europe for
the indicated use and FDA clearance is in process for the United
States with a 400 subject study in metastatic breast cancer. ANGLE
is seeking to be the first ever FDA cleared CTC harvesting system
and only the third ever FDA cleared liquid biopsy test. ANGLE has
already undertaken two separate 200 subject clinical studies under
a program designed to develop an ovarian cancer pelvic mass triage
test, with the results showing best in class accuracy (ROC-AUC) of
95.1%. The pelvic mass triage assay has undergone further
refinement and optimisation, and is currently in the process of a
200 patient clinical verification study.
ANGLE's technology for the multiplex evaluation of proteins and
nucleic acids of all types is called the HyCEAD(TM) Ziplex(R)
platform and is based on a patented flow through array technology.
It provides for low cost, highly multiplexed, rapid and sensitive
capture of targets from a wide variety of sample types. A
proprietary chemistry approach (the HyCEAD method) allows for the
capture and amplification of over 100 biomarkers simultaneously in
a single reaction. The HyCEAD Ziplex system is ideal for measuring
gene expression and other markers directly from Parsortix harvests
and was used in the ovarian cancer pelvic mass triage test to
achieve best in class accuracy (ROC-AUC) of 95.1%.
ANGLE's proprietary technologies can be combined to provide
automated, sample-to-answer results in both centralised laboratory
and point-of-use cartridge formats.
ANGLE has established formal collaborations with world-class
cancer centres and major corporates such as Abbott, Philips and
QIAGEN, and works closely with leading CTC translational research
customers. These Key Opinion Leaders (KOLs) are working to identify
applications with medical utility (clear benefit to patients), and
to secure clinical data that demonstrates that utility in patient
studies. The body of evidence as to the benefits of the Parsortix
system is growing rapidly from our own clinical studies in
metastatic breast cancer and ovarian cancer and also from KOLs with
23 peer-reviewed publications and numerous publicly available
posters, available on our website.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRALFFSIAAIVIIA
(END) Dow Jones Newswires
September 04, 2019 02:01 ET (06:01 GMT)
Angle (LSE:AGL)
Historical Stock Chart
From Apr 2024 to May 2024
Angle (LSE:AGL)
Historical Stock Chart
From May 2023 to May 2024